Boston Scientific vs Stryker
BSX and SYK side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BSX and SYK compare
Stryker is the larger company, worth 1.8 times as much as Boston Scientific ($112B against $60.8B).
On earnings, Boston Scientific is cheaper: it trades at 17.0× trailing earnings, against 31.1× for Stryker.
Boston Scientific grew revenue faster over the last twelve months (13.5% versus 7.9% for Stryker).
Stryker pays a dividend yielding 1.2%; Boston Scientific does not pay one.
Stryker scores higher on the StockData Score (19 against 14 for Boston Scientific), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BSX | SYK |
|---|---|---|
| Size and price | ||
| Market cap | $60.8B | $112B |
| Share price | $41.98 | $291.86 |
| Change, 1 year | −58.1% | −21.0% |
| Change, 5 years | −2.7% | 5.7% |
| Beta (5Y) | 0.77 | 0.85 |
| Employees | 59K | 56K |
| StockData Score | ||
| Total score | 14 | 19 (better) |
| Valuation score | 6 (better) | 4 |
| Growth score | 4 | 5 (better) |
| Performance score | 1 | 3 (better) |
| Health score | 3 | 4 (better) |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | 17.0× (better) | 31.1× |
| P/S | 2.9× (better) | 4.3× |
| P/B | 2.4× | – |
| EV/EBITDA | 13.1× (better) | 17.5× |
| P/FCF | 16.8× (better) | 24.5× |
| PEG | 0.27 (better) | 2.87 |
| FCF yield | 6.0% (better) | 4.1% |
| Fair value | $93.08 | $381.63 |
| Margin of safety | 54.9% (better) | 23.5% |
| Growth | ||
| Revenue growth (TTM) | 13.5% (better) | 7.9% |
| Revenue growth, 5Y average | 15.2% (better) | 11.8% |
| Net income growth (TTM) | – | 23.1% |
| EPS growth (TTM) | 47.0% (better) | 23.4% |
| EPS growth, 5Y average | – | 14.9% |
| Profitability | ||
| Gross margin | 69.9% (better) | 65.3% |
| Operating margin | 19.8% | 20.7% (better) |
| Net margin | – | 13.8% |
| FCF margin | 17.3% | 17.4% (better) |
| Return on invested capital | 11.2% | – |
| Financial health | ||
| Debt / equity | 0.51 | – |
| Net debt / EBITDA | 2.17 | 1.65 (better) |
| Interest coverage | 11.4× (better) | 9.3× |
| Current ratio | 1.24 | 2.18 (better) |
| Altman Z-score | 2.87 | 4.58 (better) |
| Piotroski F-score | – | 5 |
| Dividends and buybacks | ||
| Dividend yield | – | 1.2% |
| Payout ratio | – | 36.8% |
| Shareholder yield | 0.00% | 1.2% (better) |
| Ownership | ||
| Held by institutions | 92.1% | 80.2% |
| Held by insiders | 0.19% | 4.1% |
| Insider net buying, 12 months | −$13.0M (better) | −$586M |
| Superinvestors holding | 1 | 1 |
| Short interest, % of float | 2.9% | 1.6% |
Go deeper
- BSX stock overview
- BSX income statement
- BSX valuation and score
- SYK stock overview
- SYK income statement
- SYK valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.